Naohiro Yanagimura

Niigata, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

High FDG Uptake in the Non-cancerous Lung Predicts Immune-Related Adverse Events and Poor Prognosis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors.

High FDG Uptake in the Non-cancerous Lung Predicts Immune-Related Adverse Events and Poor Prognosis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors.

Journal: Academic radiology

Published: February 09, 2026

Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective study.

Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective study.

Journal: Scientific reports

Published: January 04, 2026

Sarcomatoid Transformation of Pulmonary Mucinous Adenocarcinoma as a Mechanism of Immunotherapy Resistance.

Sarcomatoid Transformation of Pulmonary Mucinous Adenocarcinoma as a Mechanism of Immunotherapy Resistance.

Journal: Thoracic cancer

Published: December 27, 2025

Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts.

Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts.

Journal: Cancer immunology, immunotherapy : CII

Published: November 24, 2025

Successful treatment with tepotinib followed by pembrolizumab in pulmonary pleomorphic carcinoma harbouring a MET exon 14 skipping mutation: A case report.

Successful treatment with tepotinib followed by pembrolizumab in pulmonary pleomorphic carcinoma harbouring a MET exon 14 skipping mutation: A case report.

Journal: Oncology letters

Published: September 25, 2025

Anti-cancer therapy and the exacerbation of pulmonary nontuberculous mycobacterial infection.

Anti-cancer therapy and the exacerbation of pulmonary nontuberculous mycobacterial infection.

Journal: Respiratory investigation

Published: May 23, 2025

Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study.

Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 02, 2025

The diagnostic value of comprehensive next-generation sequencing for genetic mutations in suspected lung cancer cases with negative pathological cytology.

The diagnostic value of comprehensive next-generation sequencing for genetic mutations in suspected lung cancer cases with negative pathological cytology.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 26, 2025

Authors' Response: FDG-PET/CT in Lung: Beyond Cancer.

Authors' Response: FDG-PET/CT in Lung: Beyond Cancer.

Journal: Academic radiology

Published: October 29, 2024

18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors.

18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors.

Journal: Academic radiology

Published: June 06, 2024

Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer.

Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer.

Journal: Journal of thoracic disease

Published: February 19, 2024

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).

Journal: Cancers

Published: December 05, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026